David Reese, Amgen
Amgen touts its latest cut of longterm Repatha data, still hunting elusive billions for PCSK9 franchise
It took 5 years for Amgen to move its PCSK9 cholesterol drug Repatha into the blockbuster column, all while waging an unending legal war over …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
